Armata Pharmaceuticals (ARMP) announced that the U.S. FDA has granted AP-SA02, the company’s Staphylococcus aureus multi-phage product candidate, for intravenous use as a Qualified Infectious Disease Product for adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureus or methicillin resistant S. aureus. The company plans to advance AP-SA02 into a Phase 3 superiority study in complicated S. aureus bacteremia, anticipated to initiate in the second half of 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARMP:
- Armata Extends Innoviva Credit, Warrants and Voting Pact
- Armata Pharmaceuticals: FDA-Endorsed Phase 3 Path and Potential QIDP Upside Support Buy Rating on AP-SA02
- Armata Wins FDA Support to Advance Bacteriophage to Phase 3
- Armata Pharmaceuticals announces End-of-Phase 2 meeting with FDA
- Armata Pharmaceuticals initiated with a Buy at JonesResearch